Abstract
The last several years have seen major progress towards the goal of translating our growing understanding of the molecular basis of cancer into drugs with improved therapeutic activity and selectivity. Tremendous advances have been made but significant obstacles remain. In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small molecule kinase inhibitors. The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents. We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches. A diverse range of kinase inhibitory scaffolds is now available based on these methods. Multi-parameter optimisation now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity. Development of a molecular audit trail requiring assays to demonstrate mechanism of action in vitro and in vivo is essential. Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.
Keywords: Cancer, kinase, inhibitor, structure-based design, selectivity, pharmacodynamics
Current Signal Transduction Therapy
Title: Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Volume: 1 Issue: 1
Author(s): Ian Collins and Paul Workman
Affiliation:
Keywords: Cancer, kinase, inhibitor, structure-based design, selectivity, pharmacodynamics
Abstract: The last several years have seen major progress towards the goal of translating our growing understanding of the molecular basis of cancer into drugs with improved therapeutic activity and selectivity. Tremendous advances have been made but significant obstacles remain. In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small molecule kinase inhibitors. The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents. We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches. A diverse range of kinase inhibitory scaffolds is now available based on these methods. Multi-parameter optimisation now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity. Development of a molecular audit trail requiring assays to demonstrate mechanism of action in vitro and in vivo is essential. Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.
Export Options
About this article
Cite this article as:
Collins Ian and Workman Paul, Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269181
DOI https://dx.doi.org/10.2174/157436206775269181 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Architectural Organization of Human Stem Cell Cycle Regulatory Machinery
Current Pharmaceutical Design Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine The Retinoblastoma Tumour Suppressor in Model Organisms-New Insights from Flies and Worms
Current Molecular Medicine Current or New Cytomegalovirus Antivirals and Novel Animal Model Strategies
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Hot Topic: Network Pharmacology: An Emerging Field in Cancer Drug Discovery)
Current Drug Discovery Technologies Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Identifying the Cellular Targets of Bioactive Small Molecules with Activity-Based Probes
Current Medicinal Chemistry Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) TGFb and its Smad Connection to Cancer
Current Genomics PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Natural Product Inhibitors of Hsp90: Potential Leads for Drug Discovery
Mini-Reviews in Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics